Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin D Mccarter

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trialChristopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Lancet (London, England)|March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialRonald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomasMorgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P Tobin, Dasha T Cogswell, Victoria M Cates, et al.
Clinical & Translational Immunology|January 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patientsVictoria M Vorwald, Dana M Davis, Robert J Van Gulick, et al.
Cells|December 17, 2024
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to ImmunotherapyIslam Eljilany, Sam Coleman, Aik Choon Tan, et al.
Science Immunology|June 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cellsWilliam H Palmer, Laura Ann Leaton, Ana Campos Codo, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trialChristopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Lancet (London, England)|March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialRonald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
Cancers|July 26, 2020
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 ImmunotherapyCarol M Amato, Jennifer D Hintzsche, Keith Wells, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomasMorgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P Tobin, Dasha T Cogswell, Victoria M Cates, et al.
Clinical & Translational Immunology|January 14, 2022
Circulating CD8<sup>+</sup> mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patientsVictoria M Vorwald, Dana M Davis, Robert J Van Gulick, et al.
Cells|December 17, 2024
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to ImmunotherapyIslam Eljilany, Sam Coleman, Aik Choon Tan, et al.
Science Immunology|June 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cellsWilliam H Palmer, Laura Ann Leaton, Ana Campos Codo, et al.
Pageof 18